CEP 8983

Drug Profile

CEP 8983

Alternative Names: CEP8983

Latest Information Update: 11 Feb 2016

Price : $50

At a glance

  • Originator Cephalon
  • Developer Checkpoint Therapeutics
  • Class Carbazoles; Piperazines; Pyrrolidinones; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Solid tumours

Most Recent Events

  • 07 Jan 2016 Checkpoint Therapeutics in-licenses CEP 8983 from Teva Pharmaceutical Industries
  • 07 Jan 2016 Clinical trials in Solid tumours in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top